Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bicarbonate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA4 | P22748 | 5/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | FAHD1 | Q6P587 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | LDHA | P00338 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bicarbonate SCHEMBL17747962 | 0.95 | CA4 (0.36) | CA4CA1FAHD1 | |
| Bicarbonate SCHEMBL2050659 | 0.95 | CA4 (0.42) | CA4CA1FAHD1LMNAMEN1 | |
| Bicarbonate SCHEMBL16039631 | 0.95 | — | — | |
| Bicarbonate SCHEMBL5488857 | 0.95 | — | — | |
| Bicarbonate SCHEMBL2304976 | 0.95 | — | — | |
| Bicarbonate SCHEMBL81419 | 0.95 | CA4 (0.42) | CA4CA1FAHD1LMNAMEN1 | |
| Bicarbonate SCHEMBL17868581 | 0.95 | CA4 (0.42) | CA4CA1FAHD1LMNAMEN1 | |
| Bicarbonate SCHEMBL6673355 | 0.95 | CA4 (0.42) | CA4CA1FAHD1LMNAMEN1 | |
| Bicarbonate SCHEMBL1003571 | 0.90 | CA4 (0.39) | CA4CA1FAHD1LMNAMEN1 | |
| Bicarbonate SCHEMBL6536657 | 0.90 | CA4 (0.39) | CA4CA1FAHD1LMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 199 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4387653-A1 | TISSUE MODIFIER AND USES THEREFOR | Foothill Saddleback Pty Ltd (AU) | 2024-06-26 | — | — | EP | claimed |
| WO-2023023776-A1 | TISSUE MODIFIER AND USES THEREFOR | Foothill Saddleback Pty Ltd (AU) | 2023-03-02 | — | — | WO | claimed |
| US-20160346274-A1 | ABUSE-RESISTANT DRUG FORMULATIONS WITH BUILT-IN OVERDOSE PROTECTION | KASHIV PHARMA, LLC (US) | 2016-12-01 | — | — | US | claimed |
| WO-2015120201-A1 | ABUSE-RESISTANT DRUG FORMULATIONS WITH BUILT-IN OVERDOSE PROTECTION | KASHIV PHARMA, LLC (US) | 2015-08-13 | — | — | WO | claimed |
| US-20120165236-A1 | CLEANSING AGENT | SHOICHI NAKAMURA (JP) | 2012-06-28 | — | — | US | claimed |
| JP-2009513512-A | — | — | 2009-04-02 | — | — | JP | claimed |
| EP-1718303-A2 | COMBINATION OF PROTON PUMP INHIBITOR, BUFFERING AGENT, AND NONSTEROIDAL ANTI-INFLAMMATORY AGENT | SANTARUS, INC. (US) | 2006-11-08 | — | — | EP | claimed |
| WO-2006116583-A2 | COMPOSITIONS COMPRISING A POLYMERIZED BENZIMIDAZOLE AND A BUFFERING AGENT AND METHODS OF USING SAME | THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 2006-11-02 | — | — | WO | claimed |
| EP-1686976-A2 | COMBINATION OF PROTON PUMP INHIBITOR AND SLEEP AID | SANTARUS, INC. (US) | 2006-08-09 | — | — | EP | claimed |
| EP-1660043-A2 | IMMEDIATE-RELEASE FORMULATION OF ACID-LABILE PHARMACEUTICAL COMPOSITIONS | The Curators of the University of Missouri (US) | 2006-05-31 | — | — | EP | claimed |
| WO-2005076987-A2 | COMBINATION OF PROTON PUMP INHIBITOR, BUFFERING AGENT, AND NONSTEROIDAL ANTI-INFLAMMATORY AGENT | SANTARUS, INC. (US) | 2005-08-25 | — | — | WO | claimed |
| US-20050112193-A1 | pH buffering agent and a controlled-release component containing an acid-labile proton pump inhibitor such as omeprazole which is protected from acid degradation in the gastrointestinal fluid by the buffer | BAUSCH HEALTH AMERICAS, INC. | 2005-05-26 | — | — | US | claimed |
| WO-2005044199-A2 | COMBINATION OF PROTON PUMP INHIBITOR AND SLEEP AID | SANTARUS, INC. (US) | 2005-05-19 | — | — | WO | claimed |
| US-20050038018-A1 | Mixture with antacids, sedatives; central nervous system stimulants; antiinflammatory agents; analgesics | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-02-17 | — | — | US | claimed |
| WO-2005009381-A2 | IMMEDIATE-RELEASE FORMULATION OF ACID-LABILE PHARMACEUTICAL COMPOSITIONS | THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 2005-02-03 | — | — | WO | claimed |
| WO-2005004915-A2 | COMPOSITIONS COMPRISING MELOXICAM | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-01-20 | — | — | WO | claimed |
| US-20040248942-A1 | Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid | THE CURATORS OF THE UNIVERSITY OF MISSOURI | 2004-12-09 | — | — | US | claimed |
| WO-2004073654-A2 | A NOVEL FORMULATION, OMEPRAZOLE ANTACID COMPLEX-IMMEDIATE RELEASE FOR RAPID AND SUSTAINED SUPRESSION OF GASTRIC ACID | SANTARUS, INC. (US) | 2004-09-02 | — | — | WO | claimed |
| US-6555137-B1 | For delayed release of an antacid in the stomach containing a coated antacid | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-04-29 | — | — | US | claimed |
| EP-1000614-A1 | SUCRALFATE-CONTAINING COMPOSITION AND PROCESS FOR THE PREPARATION THEREOF | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2000-05-17 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050112193-A1 | pH buffering agent and a controlled-release component containing an acid-labile proton pump inhibitor such as omeprazole which is protected from acid degradation in the gastrointestinal fluid by the buffer | HRH2, SI, PGA5 | CA4 299/4885CA1 206/4885FAHD1 1441/4885 |
| US-20040248942-A1 | Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid | PGA5, GIPR, ATP6AP1 | CA4 992/4885CA1 926/4885FAHD1 2995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.